Liver immunology and its role in inflammation and homeostasis

Mark W Robinson¹, Cathal Harmon¹ and Cliona O’Farrelly¹,²

The human liver is usually perceived as a non-immunological organ engaged primarily in metabolic, nutrient storage and detoxification activities. However, we now know that the healthy liver is also a site of complex immunological activity mediated by a diverse immune cell repertoire as well as non-hematopoietic cell populations. In the non-diseased liver, metabolic and tissue remodeling functions require elements of inflammation. This inflammation, in combination with regular exposure to dietary and microbial products, creates the potential for excessive immune activation. In this complex microenvironment, the hepatic immune system tolerates harmless molecules while at the same time remaining alert to possible infectious agents, malignant cells or tissue damage. Upon appropriate immune activation to challenge by pathogens or tissue damage, mechanisms to resolve inflammation are essential to maintain liver homeostasis. Failure to clear ‘dangerous’ stimuli or regulate appropriately activated immune mechanisms leads to pathological inflammation and disrupted tissue homeostasis characterized by the progressive development of fibrosis, cirrhosis and eventual liver failure. Hepatic inflammatory mechanisms therefore have a spectrum of roles in the healthy adult liver; they are essential to maintain tissue and organ homeostasis and, when dysregulated, are key drivers of the liver pathology associated with chronic infection, autoimmunity and malignancy. In this review, we explore the changing perception of inflammation and inflammatory mediators in normal liver homeostasis and propose targeting of liver-specific immune regulation pathways as a therapeutic approach to treat liver disease.

*Cellular & Molecular Immunology* (2016) 13, 267–276; doi:10.1038/cmi.2016.3; published online 11 April 2016

**Keywords:** homeostasis; immunology; inflammation; liver; tolerance

**INFLAMMATORY PROCESSES AND LIVER HOMEOSTASIS**

The human liver is classically perceived as a non-immunological organ, required for metabolic activities, nutrient storage and detoxification. We now know that the liver is also an immunologically complex organ, responsible for the production of acute phase proteins, complement components, cytokines and chemokines, and contains large, diverse populations of resident immune cells.¹⁻³ In healthy individuals, the liver is constantly bombarded by a stream of dietary and commensal bacterial products with inflammatory potential. These gut-derived molecules must be tolerated by the hepatic immune system, which, at the same time, is poised to respond to danger. In the healthy liver, constantly changing metabolic and tissue remodeling activity, combined with regular exposure to microbial products, results in persistent, regulated inflammation.

These inflammatory processes act in a tightly controlled fashion and are stimulated to additional activity only when the liver is required to rid itself of hepatotropic pathogens, malignant cells or toxic products of metabolic activity. Failure to clear such dangerous stimuli and resolve inflammation, leads to chronic infection, autoimmunity or tumor growth. This is inevitably associated with chronic pathological inflammation and disrupted tissue homeostasis, which can progress to fibrosis, cirrhosis and liver failure.

Inflammation is essential to combat infection; however, inflammatory mechanisms also underpin normal physiological events in the healthy body, including embryonic implantation,⁴ fetal development,⁵ involution post-partum and tissue repair.⁶ In the liver, homeostatic inflammatory processes control hemodynamic changes, capillary permeability, leukocyte migration into tissues and secretion of inflammatory mediators. This
homeostatic inflammation is tightly regulated and the activation of inflammatory processes is intimately linked to mechanisms that resolve inflammation and promote tissue regeneration (Figure 1). This controlled inflammation is essential to maintain tissue and organ homeostasis and yet, when dysregulated, drives pathology and organ damage (Figure 1).

In this review, we demonstrate an emerging role for inflammatory processes in normal liver homeostasis, in regulating the liver immune system and in liver regeneration following various forms of liver damage. We propose that homeostatic inflammation should be viewed as a normal part of the healthy liver and that therapeutic strategies targeting liver disease be designed to restore these homeostatic inflammatory processes.

THE IMMUNOLOGICAL STRUCTURE OF THE LIVER
The liver functions as an important buffer between gut contents and systemic circulation – 80% of the hepatic blood supply is delivered from the gut via the portal vein. This low pressure blood supply is rich with harmless dietary and environmental antigens as well as molecules from the microflora of the gut. The liver must tolerate this immunogenic load while still providing immunosurveillance for pathogenic infections and malignant cells. Upon entering the liver venous blood from the gut mixes with oxygen-rich blood from the hepatic artery and drains through the hepatic sinusoids to the central veins through plates of hepatocytes. The sinusoids are lined by specialized liver sinusoidal endothelial cells (LSEC) that contain numerous fenestrations, allowing blood to pass through the LSEC layer to the underlying hepatocytes.

This organization allows for the rapid exchange of molecules from blood into hepatocytes and facilitates the removal and degradation of immunogenic molecules (for example, bacterial endotoxin) in the liver (Figure 2). Pattern recognition receptors (PRR) expressed by hepatocytes and liver-resident macrophages (known as Kupffer cells (KC)), bind to microbial associated molecular patterns (MAMP) and damage-associated molecular patterns (DAMP), which are present in high quantities in the blood arriving from the portal vein. Upon binding, these MAMPs and DAMPs are phagocytosed and subsequently degraded by hepatocytes and KCs, without the production of inflammatory mediators that usually accompany PRR signaling. This detoxification of blood from the gut protects the rest of the body from excessive immune activation and influences the unique immunological environment within the liver.

The low pressure blood flow, fenestrated endothelium and lack of a basement membrane also facilitates intimate interactions between resident immune cells and non-hematopoietic hepatic cells. These resident immune cell populations are well recognized (for example, KCs), the full spectrum of immune cells resident within the liver is still unclear. This is particularly true in humans, and further studies are required to define phenotypically distinct liver-resident immune cell populations. While several liver-resident immune cell populations are well recognized (for example, KCs), the full spectrum of immune cells resident within the liver is still unclear. This is particularly true in humans, and further studies are required to define phenotypically distinct liver-resident immune cell populations. The context of the healthy adult liver, these liver-resident populations play vital roles in regulating inflammation and maintaining organ homeostasis and the immunological roles of individual liver-resident immune cell populations are described in further detail in this issue of Cellular and Molecular Immunology.
Liver Myeloid Immune Cell Populations

Macrophages are key detectors of microbial molecules and producers of inflammatory mediators in the body. KCs account for up to 90% of the total population of fixed macrophages in the body and constitute almost a third of the non-parenchymal cells in the liver. KCs are equipped with a massive array of PPRs, complement receptors, and Fc receptors, through which they respond with increased phagocytic activity and production of inflammatory cytokines. They have essential roles in immune regulation, tissue repair and liver regeneration and are capable of responding to cytokine, Toll-like receptor (TLR), RIG-like receptor and NOD-like receptor signaling.

Dendritic cell (DC) populations, including both myeloid DCs and plasmacytoid DCs, are found in the healthy liver. Hepatic DC populations are described as phenotypically immature although they can stimulate strong T-cell responses in certain situations. Recently a sub-population of human hepatic CD141+ DCs have been shown to be potent cytokine producers and activators of T cells.

Myeloid-derived suppressor cells (MDSC) are also present in the healthy liver and are expanded during chronic liver disease. MDSCs are defined by their ability to suppress T-cell activation through the production of the immunosuppressive molecules IL-10, transforming growth factor (TGF) β and arginase. Granulocytic cells, such as neutrophils, are thought to be largely absent in the healthy liver, only accumulating in response to infection and inflammation. However, neutrophils and their progenitors share several phenotypic markers with MDSCs and comprehensive data characterizing these populations in the human liver are lacking.

Liver Lymphoid Immune Cell Populations

The diverse range of innate lymphocytes in the adult liver includes natural killer (NK) cells, NK T cells (NKT) (including populations of CD1d-restricted invariant NKT cells), mucosal associated invariant T cells and γδ T cells. Hepatic innate lymphocyte populations are potent cytokine producers and influence both innate and adaptive immune responses in the liver. The repertoire of liver innate lymphocytes is strikingly different between mice and humans. In mice, NKT cells and NK cells make up to 40% and 10% of total liver lymphocytes respectively, while in humans, these percentages are reversed, with NK cells predominating. In humans, CD56bright NK cells are particularly enriched in the liver where they constitute over 50% of the total hepatic NK population, compared with 10–15% in peripheral blood. In mice, invariant NKT cells preferentially home to the liver where they adhere via LFA/ICAM binding, and form a highly tissue-resident immune cell population.

Populations of adaptive lymphocytes, including classic major histocompatibility complex (MHC)-restricted CD4+ and CD8+ T cells as well as B cells, are found in healthy liver. The liver is particularly enriched in CD8+ T cells, activated T cells and memory T cells. Accumulation of these T-cell subsets in the liver is associated with T-cell apoptosis and deletion leading to the liver having been described as a ‘graveyard’ for T cells. Populations of B cells are also present in the human liver, where they account for up to 8% of the total lymphocyte population. Specific hepatic B cell subpopulations, such as the innate-like CD5+ B cell population, are further expanded in the liver during hepatotropic viral infection.

Hematopoietic Progenitor Cell Populations in the Liver

While hematopoietic cell development is classically assumed to be limited to the bone marrow in healthy adults, it has been hypothesized that some hepatic immune populations differentiate locally. The ability of the liver to act as a site of hematopoiesis when under stress is well described and hematopoietic stem cells are thought to contribute to mixed chimerism following liver transplant in murine models. Moreover, purified liver hematopoietic progenitor cells have been shown to reconstitute immune cell populations following lethal irradiation in mice. The adult human liver also contains populations of progenitor cells, which express surface markers characteristic of immature hematopoietic cells and form multi-lineage hematopoietic colonies upon in vitro culture. These hepatic myeloid and lymphoid progenitor populations may contribute to the development of phenotypically distinct liver-resident immune cell populations through local hepatic immune cell differentiation.

Immune-Regulating Liver Non-Hematopoietic Cell Populations

In addition to hepatic immune cell populations, non-hematopoietic cells in the liver play key roles in local and systemic innate immunity and inflammation. LSECs, hepatocytes and hepatic stellate cells (HSC) all express a range of PRRs. Expression of TLRs, carbohydrate receptors and scavenger receptors by non-immune cells in the liver complements KC detection and clearance of MAMPs from the portal blood supply and regulates the production of inflammatory mediators from non-immune cells within the liver.

LSECs and hepatocytes express variable levels of Class II MHC molecules and are capable of presenting antigens to classical T cells. Under inflammatory conditions LSEC-primed T cells can develop into functional T effector cell populations, in the absence of CD4+ T-cell activation, and contribute to pathogen immunity. Murine hepatocytes also express the MHC-like molecule CD1d, enabling lipid presentation to invariant NKT. In contrast, it has been difficult to demonstrate CD1d expression by healthy human hepatocytes, although it is increased in the context of hepatitis C virus infection.

THE LIVER MICROENVIRONMENT AND IMMUNE REGULATION

The anatomical structure, resident immune cell repertoire and state of constant stimulation in the liver combine to create a unique cytokine/growth factor milieu. This microenvironment determines the balance between tolerance and inflammation in the healthy liver. The hepatic blood supply is a significant contributor to the unique liver microenvironment. Cells within the liver are subject to persistent signaling from dietary and commensal molecules, which induces a state of tolerance as
discussed in more detail below. The healthy adult liver has an active and complex cytokine milieu, which includes basal expression of pro-inflammatory (IL-2, IL-7, IL-12, IL-15 and interferon (IFN)γ) and anti-inflammatory (IL-10, IL-13 and TGFβ) cytokines. This cytokine milieu exists in the absence of infection or pathological inflammation, and presumably arises through normal physiological processes within the healthy liver. These processes likely include PRR signaling induced by gut-derived molecules in both non-hematopoietic and myeloid cell populations, as well as cytokine production by activated hepatic lymphoid immune cell populations.

The hepatic microenvironment is further influenced by the high levels of dietary fats and carbohydrates in the hepatic blood supply. Carbohydrates are taken up by hepatocytes and stored as glycogen, while dietary fats, transported from the gut as chylomicrons, are processed into a range of lipoproteins that in turn distribute cholesterol and triglycerides throughout the body (Figure 2). Importantly these metabolic processes are intimately linked to liver inflammation through the inflammatory effects of metabolites such as succinate as well as triglyceride and cholesterol levels, which promote TLR signaling and inflammasome activation. The metabolic regulation of inflammation is important in non-alcoholic fatty liver disease where elevated pro-inflammatory cytokines, which contribute to liver fibrosis, are observed. In mouse models, this pro-inflammatory profile can be replicated by a high-fat diet, driven in part by the sensitization of hepatocytes to TLR agonists by saturated fatty acids. Metabolic regulation of liver hepatocytes is also evident in hepatitis B virus and hepatitis C virus infections, where metabolic changes in infected hepatocytes promote viral replication. It is likely that these metabolic changes also influence the inflammatory immune response to viral infection.

Indeed, these metabolic links with inflammation extend beyond hepatocytes and also influence macrophage and DC functions. Both macrophages and DCs undergo metabolic reprogramming upon activation, switching from oxidative phosphorylation to aerobic glycolysis, termed the Warburg effect. This switch is essential for the production of pro-inflammatory mediators in macrophages however the influence of metabolism on liver KC function is presently unknown. At normoxia, the switch to aerobic glycolysis in macrophages results in increased succinate levels that in turn activate HIF1α and IL1β production. HIF1α is also activated by hypoxia yet despite the liver being in a constant state of low oxygen tension (due to blood from the portal vein), a hypoxia response is not induced in healthy hepatic cells. This suggests that cells within the liver may have a unique response to metabolic signals that are known to drive inflammation and these unique metabolic signals likely contribute to the regulation of liver-immigrating immune cell populations. A deeper understanding of the role of the dynamic liver microenvironment in organ homeostasis is required to provide a context to the changes that occur during human liver pathology.

INFLAMMATORY PROCESSES IN THE HEALTHY LIVER
Inflammation and inflammatory mediators, generated by liver-resident immune cell populations and non-hematopoietic cells, play essential roles in maintaining local liver and systemic homeostasis. These homeostatic roles must be recognized when considering the role of inflammation and liver-resident immune cell populations in liver disease and pathology. Liver inflammation should be considered as a highly dynamic and complex network of responses, which collectively aim to maintain organ and also systemic homeostasis in healthy individuals.

The Tolerogenic Liver
The healthy liver is often described as being immunologically tolerant, nevertheless it is evident that rapid and robust liver immune responses are successfully generated in many circumstances. The concept that the liver is an immunologically tolerant organ arose in the transplantation field when it was first observed in pigs that allogeneic liver transplantation was significantly better tolerated than other allogeneic organ transplantation, which induced rapid rejection. This concept is supported by the low levels of immunosuppression generally required by liver transplant recipients. Indeed, in certain individuals, immunosuppression can be completely stopped following liver transplantation without subsequent graft rejection. Furthermore, the ability of hepatic tolerance to induce systemic tolerance to co-transplanted organs highlights the powerful tolerogenic properties of the liver.

 Resident myeloid cells contribute to the maintenance of hepatic tolerance. KCs respond to bacterial endotoxin by producing anti-inflammatory cytokines such as IL-10 and prostaglandins. These downregulate expression of co-stimulatory molecules on APCs, preventing activation of CD4+ T cells and limiting the adaptive immune response. Presentation of particulate antigens by KCs preferentially expands IL-10 producing T regulatory cell populations inducing antigen-specific tolerance. Similarly, hepatic myeloid DCs are less potent activators of T cells and produce significantly more IL-10 compared with spleen derived myeloid DCs. Hepatic plasmacytoid DCs also appear phenotypically immature and are not effective T-cell activators ex vivo; however, activation via growth factors or TLR agonists induces maturation and effective antigen presentation. Hepatic plasmacytoid DCs have also been shown to be capable of IL-10 production and activation of regulatory T cells. In addition to these professional APC populations in the liver, LSECs and hepatocytes possess the ability to directly present antigen to T cells. Under certain conditions HSCs may also directly present antigen to T cells as well as influence antigen presentation as a bystander cell. The presentation of antigens in the liver biases T cells towards tolerance due to a lack of co-stimulatory molecules and CD4+ T-cell help, required for efficient T-cell differentiation.

The tolerogenic liver environment is further maintained by regulatory myeloid populations such as MDSCs. MDSCs mediate their suppressive activity through the production of the immunosuppressive cytokines IL-10 and TGFβ, and the
production of arginase and IDO, which limit essential amino acids required for immune cell activation and proliferation. Transmigration of monocytes through LSECs leads to MDSC differentiation and MDSCs are activated during the liver acute phase response, contributing to the immunoregulatory potential of the liver.

Systemic Homeostasis and the Acute Phase Response
A key systemic function of the liver is serum protein production. The liver normally synthesizes the majority of serum proteins, including complement proteins, albumin, fibrinogen, clotting factors, transport proteins, protease inhibitors and lipoproteins (Figure 3). These proteins are involved in the systemic transport of nutrients, in the regulation of blood osmotic pressure and act as inactive precursors of several innate immune mediators. The liver also has a central role in detecting and responding to inflammatory signals from other sites in the body (Figure 3). During the early stages of extra-hepatic inflammation, cytokines produced by immune cells enter the blood stream and are detected by liver hepatocytes, which initiate the systemic acute phase response (APR). Hepatocytes increase acute phase protein production by orders of magnitude and also synthesize IL-6, which acts to amplify the APR.

The acute phase proteins produced by hepatocytes have direct effector function (Table 1) and are responsible for the systemic effects of inflammation, which promote pathogen clearance. The acute phase proteins drive a range of mechanisms throughout the body including leukocytosis in the bone marrow, changes in the brain that mediate pyrexia and alter behavior, and massive immune cell infiltration to the site of initial inflammation. At the same time the APR includes a range of processes to limit excessive inflammation. These processes include the inhibition of neutrophil function by protease inhibitors, such as α2-macroglobulin, the inhibition of TNF production from KC by C-reactive protein, and the recruitment of suppressive MDSC populations by serum amyloid A. These processes act to limit bystander tissue damage caused by the inflammatory process and enhance the repair process.

Liver Immunity and Resolving Fibrosis
While maintaining an overall tolerogenic environment, the hepatic immune system must be capable of rapid, controlled responses to tumor cells and pathogenic microorganisms. Many pathogens, including several species of viruses, bacteria and parasites, specifically target the liver. Effective local immunity is essential for detecting and clearing these hepatotropic pathogens. During acute liver insult activated KCs can become potent producers of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α as well chemokines such as MIP-1α and RANTES. This KC pro-inflammatory response is induced following signaling via MyD88-independent TLRs (for example, TLR3), but not MyD88-dependent pathways, which instead induce IL-10 production. Potent pro-inflammatory CD141+ myeloid DCs have also been demonstrated in healthy adult liver, capable of inducing IFN-γ and IL-17 production from T cells. In this inflammatory microenvironment, liver-primed T cells can develop into functional T effector cell populations and mediate pathogen clearance, even in the absence of classical CD4+ T cell help.

Acute liver inflammation leads to the recruitment and activation of leukocyte populations, and the induction of fibrotic responses at the site of inflammation, as summarized in Figure 4. The resolving fibrosis observed during acute injury acts to protect surviving hepatocytes by reducing pro-apoptotic signaling and increasing resistance to a range of toxins. This fibrotic process is regulated by inflammatory cytokines and growth factors, released by leukocytes that traffic to the damaged tissue. These cytokines include TNFα, IL-6, platelet-derived growth factor and TGFβ. These cytokines lead to activation and proliferation of HSCs, which are potent producers of extracellular matrix components, including α-smooth muscle actin and type I collagen. Liver fibrosis is
often considered a feature of pathology but resolving fibrosis is also essential for liver wound repair and restoration of tissue homeostasis (Figure 4). Fibrosis only becomes clinically relevant when it alters tissue structure and function due to dysregulated or excessive inflammation.

In the resolution phase of acute liver fibrosis, macrophages produce a range of pro-resolution mediators, which increase expression of matrix metalloproteinases and suppress matrix metalloproteinase inhibitors. At the same time, NK cell-mediated cytotoxicity against HSCs contributes to the regulation of intrathepatic fibrosis. Trans-differentiation of activated HSCs into myofibroblasts alters the balance of activating and inhibitory cell receptor ligands such that they are targeted for deletion by NK cells via TRAIL-, FasL- and NKG2D-dependent mechanisms. These multifaceted interactions between immune cell subsets that regulate the repair process lead many to consider wound healing as a critical component of the innate immune response to tissue damage.

Table 1 Serum protein synthesis by the liver during the acute phase response

| Proteins induced in APR | Examples | Immune function |
|-------------------------|----------|-----------------|
| Complement proteins     | C3, C4 and C9 | Enhance phagocytosis, act as chemoattractants, induce cell degranulation, enhance vascular permeability and induce bacterial cell lysis |
| Iron-binding proteins   | Haptoglobin, hemopexin, ferritin and hepcidin | Act to reduce free iron in the serum and antimicrobial functions |
| Antimicrobial proteins  | Liver expressed antimicrobial peptide 2, hepcidin | Antimicrobial activity |
| Clotting factors        | Fibrinogen, prothrombin, factor VIII, factor IX and Von Willebrand factor | Enhance coagulation |
| Inflammatory proteins   | IL-6, lippopolysaccharide-binding protein and secreted phospholipase A2 | Enhance pro-inflammatory signals and potentiate the APR |
| Lectins, pentraxins, ficolins and collectins | C-reactive protein, mannose-binding lectin, collectin liver 1, ficolin-2 and serum amyloid P | Active complement and enhance phagocytosis |
| Protease inhibitors     | α2-Macroglobulin, α1-antichymotrypsin and α1-antitrypsin | Anti-inflammatory functions via the inhibition of coagulation, neutrophils and mast cells |

Abbreviation: ARP, acute phase response.
Inflammation and Liver Regeneration

The capacity of the liver to fully regenerate after injury is essential for the maintenance of the liver’s important functions in the control of metabolism and xenobiotic detoxification. This regenerative capacity is driven by the proliferation of existing mature hepatocytes in response to environmental cues. The regeneration potential of the liver is driven by inflammatory mediators (for example, IL-1α, TNFα and IL-6), growth factors (for example, hepatocyte growth factor and epidermal growth factor) and liver-resident immune cell populations. The importance of IL-6 is emphasized by the impaired liver regeneration observed in mice with targeted disruption of IL-6, which have reduced hepatocyte proliferation that can be restored with a single pre-operative dose of IL-6. Impaired liver regeneration is also observed in mice treated with antibodies targeting TNFα. The pro-regeneration effect of TNFα requires expression of inducible nitric oxide synthase, which blocks the potential pro-apoptotic effect of TNFα signaling, and highlights a small part of the complexity of inflammatory signals required to regulate liver regeneration.

KC s play a central role in this liver regeneration via release of IL-6 and TNFα, which promotes hepatocyte proliferation, and KC depletion impedes subsequent liver regeneration. This KC activation is driven by neutrophil recruitment to the liver, in response to inflammatory signals, in an ICAM-1-dependent manner. The complement proteins C3 and C5 also play important roles in priming KCs and promoting hepatocyte proliferation following partial hepatectomy. In addition to these pro-regeneration properties, liver-resident immune cell populations can also inhibit liver regeneration. Depletion of NK cells enhances liver regeneration due to reduced IFNγ production, which acts to induce hepatocyte cell cycle arrest and inhibits hepatocyte proliferation. Depletion of NKT cells in hepatitis B virus transgenic mice also enhances liver regeneration due to reduced production of IFNγ and TNFα. These liver-resident immune cell populations act as a negative feedback mechanism, regulating liver regeneration and returning the liver to homeostasis.

TARGETING IMMUNE DYSREGULATION AS A THERAPEUTIC STRATEGY IN LIVER DISEASE

Disregulation of liver inflammation is a hallmark of chronic infection, autoimmune and malignancy, which is mediated by multiple overlapping pathways in different liver diseases. While homeostatic inflammation and liver fibrosis are aspects of the healthy adult liver, a lack of resolution or chronic liver injury lead to progressive liver fibrosis and permanent liver damage. In these situations, pathological inflammation promotes the progression of liver fibrosis to cirrhosis and establishes a dysregulated balance between inflammation and immunosuppression within the liver. Approaching liver disease as a range of overlapping pathways leading to the dysregulation of homeostatic inflammatory processes provides novel avenues for the development of future therapies targeting inflammation and resolution within the liver.

Excessive or persistent inflammation characterizes a range of liver diseases. Persistent activation of innate immune detection pathways, due to chronic infection, tissue damage, excess consumption of alcohol or fat, or tumor growth, leads to the classic features of pathological liver inflammation. Persistent inflammatory signals, produced by a range of immune cell and non-hematopoietic cell populations, maintain HSC-derived hepatic myofibroblasts in an activated state. This limits myofibroblast senescence and reduces the ability of NK cells to induce myofibroblast apoptosis. Within the diseased liver, excessive inflammation results in the loss of liver tolerogenic mechanisms, promoting further inflammation. Inflammatory monocyte-derived macrophages are recruited to the liver where they promote fibrosis, and reduce the ability of KCs to promote T regulatory cell development. This disruption of hepatic tolerance has important clinical consequences as liver disease develops. As an example the spread of bacterial products in advanced cirrhosis/decompensation can lead to a pro-inflammatory cytokine storm and eventual systemic organ failure. Where treatment options are available clinically, such as in autoimmune disorders, these rely on the use of general immunosuppressive drugs. In this context, therapeutic strategies aimed at enhancing the normal tolerogenic liver mechanisms that lead to the resolution of inflammation, fibrosis regression and hepatocyte regeneration, may augment the existing immunosuppressive treatments. The potential of such strategies can be seen in results from a recent clinical trial, using a combination of granulocyte colony-stimulating factor and erythropoietin to enhance liver regeneration, which improved 12-month survival for patients with advanced cirrhosis and significantly reduced liver severity scores.

Normal liver tolerogenic mechanisms can also act to promote the persistence of liver pathogens, such as hepatitis C virus, and the growth of primary and metastatic tumors, which in time establishes a state of dysregulated inflammation. A number of pathogens specifically target the liver and the liver is also a common site of primary malignancy and metastasis. The presentation of pathological antigens in the liver can actively suppress immune responses, thus inducing a state of immune tolerance to the pathogen or tumor. At the same time, innate immune activation, in response to MAMPs or DAMPs released during infection or tumor growth, results in persistent inflammation and the upregulation of a number of immune regulatory pathways aimed at minimizing excessive tissue damage. This includes expansion of tumor-promoting immunoregulatory cell populations such as MDSCs, epigenetic and metabolic changes resulting in immune cell tolerance, induction of negative regulators of pro-inflammatory signaling pathways, and development of T-cell exhaustion. Targeting these immune regulatory pathways in liver disease could reduce liver pathology (via promotion of regulatory mechanisms) or induce pathogen/tumor clearance (via inhibition of regulatory mechanisms). One such strategy, using immune checkpoint inhibitors to reverse T-cell exhaustion, is showing promise in the field of cancer therapy as well as in the context of liver disease. A phase
II clinical trial of Tremelimunab (which targets cytotoxic T-lymphocyte-associated protein 4), in patients with hepatitis C virus infection and hepatocellular carcinoma, resulted in favorable antitumor activity and antiviral activity, including transient complete viral response in three patients.\textsuperscript{112} These results highlight the potential for therapeutically targeting immune tolerance in the liver.

**EPILOGUE: THE HEALTHY IMMUNOLOGICAL LIVER**

Inflammatory mechanisms are crucial to maintaining liver homeostasis as well as protecting the body from pathogens, tumors and tissue damage. Hepatic inflammatory mechanisms initiate, mediate and resolve systemic and local immune responses and at the same time contribute to liver pathology. The diverse repertoire of immune cell populations in the liver, together with the inflammatory potential of non-hematopoietic hepatic cells, plays a central role in both homeostatic and pathological inflammation within the liver. The complex inflammatory and immunoregulatory interplay within the liver is required to maintain organ and systemic homeostasis, as well as mobilize complementary inflammatory mechanisms to protect against infection, metastasis and tissue damage. We are at last beginning to dissect out the molecular mechanisms involved in these apparently contradictory inflammatory processes and to understand how inflammation is responsible for both normal liver homeostasis and function and also for liver pathology.

**KEY CONCEPTS**

1. The healthy adult liver contains large populations of resident myeloid and lymphoid immune cells.
2. Inflammatory mechanisms in the healthy liver maintain local organ and systemic homeostasis.
3. Despite a bias toward immune tolerance, hepatic immune cells can induce robust pro-inflammatory responses upon tissue damage or infection.
4. The liver plays a central role in the sensing of and the response to systemic inflammation.
5. Excessive or dysregulated inflammatory activity leads to the pathology associated with autoimmune, infectious or malignant hepatic disease.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

We acknowledge funding from Science Foundation Ireland (grant # 12/IA/1667) and the Health Research Board (grant # HRA-POR-2013-424). In addition, we gratefully acknowledge the on-going research contributions from the Liver Transplant Unit at St. Vincent’s University Hospital.

---

1. Crispe IN. The liver as a lymphoid organ. *Annu Rev Immunol* 2009; 27: 147–163.
Inflammation and liver homeostasis

MW Robinson et al

26 Kenna T, Golden-Mason L, Norris S, Hegarty JE, O’Farrelly C, Doherty DG. Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver. Clin Immunol 2004; 113: 56–63.

27 Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O’Farrelly C et al. NKT cells from normal and tumor-bearing human liver are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003; 171: 1775–1783.

28 Dusseaux M, Martin E, Serriani N, Péguillet I, Premel V, Louis D et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117: 1250–1259.

29 Gao B, Jeong W-I, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2007; 48: 729–736.

30 Hatefi K, Van Thiel DH, Herberman RB, Whiteside TL. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology 1991; 14: 495–503.

31 Moroso V, Metselaar HJ, Mancham S, Tilaus HW, Eissens D, van der Meer A et al. Hepatic interleukin 15 (IL-15) expression: implications for local NK/NKT cell homeostasis and development. Clin Exp Immunol 2004; 138: 94–101.

32 Lynch L, Michelet X, Zhang S, Brennan PJ, Moscow A, Luster C et al. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of Treg cells and macrophages in adipose tissue. Nat Immunol 2015; 16: 85–95.

33 Pruvot FR, Navarro F, Janin A, Labalette M, Masy E, Leconte-Houcke M et al. Characterization, quantification, and localization of passenger T lymphocytes and CD1d-expressing NK cells in human liver before transplantation. Transpl Int 1995; 8: 273–279.

34 Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999; 163: 3202–3210.

35 Huang L, Soldavila G, Leeker M, Flavell R, Crispe IN. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity 1994; 1: 741–749.

36 Raccura V, Sansonno D, Piccoli C, D’Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001; 167: 21–29.

37 Curry MP, Golden-Mason L, Doherty DG, Daignan T, Norris S, Duffy M et al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol 2003; 38: 642–650.

38 Golden-Mason L, Curry MP, Nolan N, Traynor O, McEntee G, Kelly J et al. Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver. Hepatology 2000; 31: 1251–1256.

39 Crosbie OM, Reynolds M, McEntee G, Traynor O, Hegarty JE, O’Farrelly C. In vivo evidence for the presence of hematopoietic stem cells in the adult human liver. Hepatology 1999; 29: 1193–1198.

40 Taniguchi H, Toyoshima T, Fukao K, Nakauchi H. Presence of hematopoietic stem cells in the adult liver. Nat Med 1996; 2: 198–203.

41 Jiang X, Chen Y, Wei H, Sun R, Tian Z. Characterizing the lymphopoietic kinetics and features of hematopoietic progenitors contained in the adult murine liver in vivo. PLoS One 2013; 8: e76762.

42 Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013; 14: 996–1006.

43 Seki E, Brenner D. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322–335.

44 Böttcher JP, Schanz O, Wohleber D, Abdullah Z, Deby-Pascher S, Staratschek-Jox A et al. Liver-primed memory T cells generated during noninflammatory conditions provide anti-infectious immunity. Cell Rep 2013; 3: 779–795.

45 Yang L, Jhaveri R, Huang J, Qi Y, Diehl AM. Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007; 87: 927–937.

46 Yanagisawa K, Yue S, van der Vliet HJ, Wang R, Alatrakchi N, Golden-Mason L et al. Ex vivo analysis of resident hepatic pro-inflammatory CD1d-negative T cells and hepatocyte surface CD1d expression in hepatitis C. J Viral Hepat 2013; 20: 556–565.

47 Kelly AM, Golden-Mason L, Traynor O, Geoghegan J, McEntee G, Hegarty JE et al. Changes in hepatic immunoregulatory cytokines in patients with metastatic colorectal carcinoma: implications for hepatitis anti-tumor immunity. Cytokine 2006; 35: 171–179.

48 Golden-Mason L, Kelly AM, Doherty DG, Traynor O, McEntee G, Kelly J et al. Hepatic interleukin 15 (IL-15) expression: implications for...
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/